kringle-pharmaCo., Ltd.

NEWS

notice

Dec 22, 2017 Notice

Kringle Pharma announces completion of participant enrollment in the Phase I/II study of recombinant human HGF for acute spinal cord injury.

Kringle Pharma announces completion of participant enrollment in the Phase I/II study of recombinant human HGF for acute spinal cord injury.